First-in-Patient Study to Assess the Safety and Tolerability and to Explore the Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Monotherapy and as Add-On Therapy in Patients With Schizophrenia.

Trial Profile

First-in-Patient Study to Assess the Safety and Tolerability and to Explore the Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Monotherapy and as Add-On Therapy in Patients With Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs ADX 71149 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
    • 28 May 2013 Data has been presented at the 2013 Annual Meeting of the American Psychiatry Association, according to an Addex Therapeutics media release.
    • 05 Nov 2012 Results from the double-blind component o the trial (part B) have been reported in an Addex Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top